Articles

Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma

Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Hemato-Oncology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center, Omaha, NE
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
University of Colorado Cancer Center, Aurora, CO
University of Colorado Cancer Center, Aurora, CO
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Haematologica Early view Nov 19, 2026 https://doi.org/10.3324/haematol.2026.301578